Enovis (C520) Stock Price & Analysis
C520 Stock Chart & Stats
- Day’s Range
- EUR 20.00 - EUR 20.00
- 52-Week Range
- EUR 15.40 - EUR 27.80
- Previous Close
- EUR 19.40
- Volume
- 0
- Average Volume (3M)
- 3
- Market Cap
- EUR 1.02B
- Enterprise Value
- EUR 2.65B
- Total Cash (Recent Filing)
- EUR 12.56M
- Total Debt (Recent Filing)
- EUR 1.37B
- Price to Earnings (P/E)
- ―
- Beta
- 0.99
- Next Earnings
- Nov 05, 2026 (Est.)
- EPS Estimate
- 0.68
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Organic Growth And Share Gains
Positive organic growth across both segments, particularly in Reconstruction, indicates continued demand and commercial execution. Growth in hips, knees, shoulders, and extremities, together with reported share-gain opportunities, can support durable revenue expansion over the next several quarters.
Product Innovation And Adoption
Nebula conversions and the commercial launch of ARVIS strengthen Enovis’s technology and product portfolio. Adoption by competitive users and positive early feedback can deepen surgeon engagement, support account wins, and create a foundation for sustained share gains.
Improving Cash Flow And Margins
Improving margins and sharply higher free cash flow show progress toward better earnings quality and internal funding capacity. Reaffirmed expectations for over 25% free-cash-flow conversion would strengthen debt reduction and provide more flexibility for innovation and growth investment.
Bears Say
Large Ongoing Net Losses
Very large reported losses remain the clearest fundamental weakness and indicate that revenue growth has not yet translated into consistent GAAP earnings power. Until profitability improves materially, Enovis may have less resilience to operational setbacks and less capacity to fund expansion from earnings.
Elevated Leverage
Leverage near the level of equity limits financial flexibility relative to a less indebted balance sheet. Although management is targeting leverage below three times, debt reduction depends on sustained cash generation, making capital allocation and execution more consequential over the coming quarters.
Inflation And Pricing Pressure
Persistent inflation can pressure margins when contractual and competitive conditions prevent full price recovery. The issue is especially relevant in Prevention & Recovery, where management has already identified difficulty passing through costs, potentially limiting the durability of margin expansion.
Enovis News
C520 FAQ
What was Enovis’s price range in the past 12 months?
What is Enovis’s market cap?
When is Enovis’s upcoming earnings report date?
How were Enovis’s earnings last quarter?
Is Enovis overvalued?
Does Enovis pay dividends?
What is Enovis’s EPS estimate?
How many shares outstanding does Enovis have?
What happened to Enovis’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Enovis?
What is the TipRanks Smart Score and how is it calculated?
Enovis Stock Smart Score
Company Description
Enovis
Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionals—including orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainers—who treat patients with musculoskeletal conditions resulting from degenerative illnesses, deformities, traumatic events, or sports-related injuries. The company's extensive product line encompasses rigid and flexible orthopedic supports, thermal and cryotherapy items, bone growth stimulation devices, vascular therapy systems paired with compression garments, therapeutic footwear and orthotics, electrical stimulators for pain alleviation, and physical rehabilitation equipment. Additionally, Enovis provides a comprehensive array of reconstructive joint implants for areas such as the hip, knee, shoulder, elbow, foot, ankle, and fingers. Enovis Corporation distributes its products through a network of independent channels, including healthcare providers, retail establishments, and pharmacies, in addition to direct sales under its prominent DJO brand. Previously known as Colfax Corporation, the company is headquartered in Wilmington, Delaware.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Damien McDonald
- Employees
- 7,802
- Website
- www.enovis.com
- Address
- 2900 Lake Vista Drive, Lewisville, TX, 75067, US
Enovis (C520) Earnings & Revenues
C520 Company Deck
C520 Earnings Call
Earnings Call SentimentPositive
The call was broadly positive. Enovis delivered 5% organic growth, strong U.S. Recon and new-product momentum, improved margins, higher adjusted EPS, a significant improvement in free cash flow, and progress on deleveraging while reaffirming 2026 guidance. The principal challenges were inflation, tariffs, Middle East-related disruption, softer Western European markets, and a seasonally more difficult third quarter, but management expressed confidence in commercial execution and second-half acceleration.
View all DE:C520 earnings summariesC520 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 2 | 4 |
| Technical Analysis | 3 | 2 | 4 |
| Moving Averages | 12 | 0 | 0 |